Literature DB >> 20597917

Testing for CHEK2 in the cancer genetics clinic: ready for prime time?

S A Narod1.   

Abstract

The 1100delC mutation of the CHEK2 gene was found to be a cause of breast cancer in 2002. The lifetime risk of breast cancer among women with a mutation and with a family history of breast cancer is approximately 25%. These women are good candidates for screening with MRI and for chemoprevention with tamoxifen. It is reasonable to test for this single mutation when women undergo testing for BRCA1 and BRCA2.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20597917     DOI： 10.1111/j.1399-0004.2010.01402.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN： 0009-9163            Impact factor:   4.438


  23 in total

1.  The tip of the iceberg: a countercurrents series.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

2.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.

Authors:  Silvia Casadei; Barbara M Norquist; Tom Walsh; Sunday Stray; Jessica B Mandell; Ming K Lee; John A Stamatoyannopoulos; Mary-Claire King
Journal:  Cancer Res       Date:  2011-02-01       Impact factor: 12.701

3.  CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families.

Authors:  L Fachal; M Santamariña; A Blanco; A Carracedo; A Vega
Journal:  Clin Transl Oncol       Date:  2012-11-13       Impact factor: 3.405

Review 4.  Breast cancer in young women.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2012-06-26       Impact factor: 66.675

Review 5.  Next-generation sequencing for inherited breast cancer risk: counseling through the complexity.

Authors:  Irene R Rainville; Huma Q Rana
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

6.  Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.

Authors:  Dorothea Gadzicki; D Gareth Evans; Hilary Harris; Claire Julian-Reynier; Irmgard Nippert; Jörg Schmidtke; Aad Tibben; Christi J van Asperen; Brigitte Schlegelberger
Journal:  J Community Genet       Date:  2011-03-02

7.  RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.

Authors:  Åsa Ehlén; Björn Nodin; Elton Rexhepaj; Jenny Brändstedt; Mathias Uhlén; Maria Alvarado-Kristensson; Fredrik Pontén; Donal J Brennan; Karin Jirström
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

8.  Response to DNA damage of CHEK2 missense mutations in familial breast cancer.

Authors:  Wendy Roeb; Jake Higgins; Mary-Claire King
Journal:  Hum Mol Genet       Date:  2012-03-13       Impact factor: 6.150

Review 9.  Bilateral breast cancers.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2014-02-04       Impact factor: 66.675

10.  Cancer risk assessment using genetic panel testing: considerations for clinical application.

Authors:  Susan Hiraki; Erica S Rinella; Freya Schnabel; Ruth Oratz; Harry Ostrer
Journal:  J Genet Couns       Date:  2014-03-07       Impact factor: 2.537
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.